Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The attachment inhibitor plus an optimized antiretroviral background regimen suppressed HIV in the majority of study participants.
The Conference on Retroviruses and Opportunistic Infections in Seattle saw many important studies that are advancing the fight against HIV.
Researchers followed a small group of people with highly drug-resistant virus taking injectable antibody.
Researchers gave the antibody treatment to those with multidrug-resistant HIV along with an optimized antiretroviral regimen.
Fostemsavir offers HIV treatment hope to those with no other options.
In a recent trial, the investigational entry inhibitor helped fully suppress HIV in a majority of those with multidrug-resistant virus.
A long-term HIV survivor reflects on the gaps and challenges that remain to end the epidemic.
Nelson Vergel pushes for the development of new salvage therapies.
In an ongoing trial of people on failing antiretroviral regimens, the injectable PRO 140 reduced viral load considerably.
The Food and Drug Administration approves antibody treatment Trogarzo for multidrug-resistant HIV.
The intravenous medication, which should be used with standard antiretrovirals, has a wholesale acquisition cost of $118,000 per year.
Early results from an ongoing trial show that 24 weeks after adding the drug to their HIV regimen, half were virally suppressed.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.